According to Insight Life's announcement, 6 medical device registration applications declared by the company and its holding subsidiary Meishbio were accepted by the Shanghai Drug Administration. Among them, the company declared 4 class II in vitro diagnostic reagents for the auxiliary diagnosis of Alzheimer's disease, and 2 auxiliary diagnostic reagents for the evaluation of abnormal hormonal diseases and fat-soluble vitamins, respectively. The application is currently being accepted, and subsequent processes such as technical review are required. The acceptance of the application has no impact on recent performance, and whether it can be approved is yet to be determined by the final review.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.